Does LENVATINIB Cause Immune-mediated hepatitis? 86 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 86 reports of Immune-mediated hepatitis have been filed in association with LENVATINIB (Lenvima). This represents 0.3% of all adverse event reports for LENVATINIB.
86
Reports of Immune-mediated hepatitis with LENVATINIB
0.3%
of all LENVATINIB reports
11
Deaths
58
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From LENVATINIB?
Of the 86 reports, 11 (12.8%) resulted in death, 58 (67.4%) required hospitalization, and 6 (7.0%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for LENVATINIB.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Malignant neoplasm progression (2,929)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
PEMETREXED (86)
TREMELIMUMAB (51)
Which LENVATINIB Alternatives Have Lower Immune-mediated hepatitis Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE